Department of Physiology, Faculty of Medicine, Harran University, Sanliurfa 63290, Turkey.
Department of Biophysics, Faculty of Medicine, Harran University, Sanliurfa 63290, Turkey.
Medicina (Kaunas). 2024 Oct 20;60(10):1717. doi: 10.3390/medicina60101717.
: Atherosclerosis, driven by dyslipidaemia and oxidative stress, is a leading cause of cardiovascular morbidity and mortality. This study evaluates the effects of vigorous-intensity bodybuilding exercise (VIBBE) on atherosclerosis biomarkers-including paraoxonase-1 (PON1) and arylesterase (ARE) activities-and lipid profiles in male bodybuilders who do not use anabolic-androgenic steroids. Comparisons were made with individuals engaged in moderate-intensity aerobic exercise (MIAE), as well as overweight/obese sedentary (OOS) and normal-weight sedentary (NWS) individuals. : A cross-sectional study was conducted involving 122 healthy male participants aged 18-45 years, divided into four groups: VIBBE ( = 31), OOS ( = 30), MIAE ( = 32), and NWS ( = 29). Anthropometric assessments were performed, and fasting blood samples were collected for biochemical analyses, including lipid profiles and PON1 and ARE activities. Statistical analyses compared the groups and evaluated correlations between adiposity measures and atherosclerosis biomarkers. : The VIBBE group exhibited significantly lower levels of low-density lipoprotein cholesterol (LDL-C), triglycerides (TG), and logarithm of the TG to high-density lipoprotein cholesterol (HDL-C) ratio [log(TG/HDL-C)] compared to the OOS group ( < 0.05 for all), indicating improved lipid profiles. However, these improvements were not significant when compared to the NWS group ( > 0.05), suggesting that VIBBE may not provide additional lipid profile benefits beyond those associated with normal weight status. PON1 and ARE activities were significantly lower in the VIBBE group compared to the MIAE group ( < 0.05 for both), suggesting that VIBBE may not effectively enhance antioxidant defences. Correlation analyses revealed significant inverse relationships between PON1 and ARE activities and adiposity measures, including body mass index (BMI), waist-to-hip ratio (WHR), waist-to-height ratio (WHtR), body fat percentage (BFP), fat mass index (FMI), and obesity degree (OD) ( < 0.05 for all). Positive correlations were observed between oxLDL and log(TG/HDL-C) and adiposity measures ( < 0.05 for all). : Vigorous-intensity bodybuilding exercise improves certain lipid parameters compared to sedentary obese individuals but does not significantly enhance antioxidant enzyme activities or further improve lipid profiles beyond those observed in normal-weight sedentary men. Conversely, moderate-intensity aerobic exercise significantly enhances PON1 and ARE activities and improves lipid profiles, offering superior cardiovascular benefits. These findings underscore the importance of incorporating moderate-intensity aerobic exercise into physical activity guidelines to optimize cardiovascular health by balancing improvements in lipid metabolism with enhanced antioxidant defences.
动脉粥样硬化是心血管发病率和死亡率的主要原因,其由血脂异常和氧化应激驱动。本研究评估了高强度健身运动(VIBBE)对不使用合成代谢雄激素类固醇的男性健美运动员的动脉粥样硬化生物标志物——包括对氧磷酶 1(PON1)和芳酯酶(ARE)活性——和血脂谱的影响,并与进行中等强度有氧运动(MIAE)的个体以及超重/肥胖静坐(OOS)和正常体重静坐(NWS)个体进行了比较。
一项涉及 18-45 岁 122 名健康男性参与者的横断面研究将参与者分为四组:VIBBE(n=31)、OOS(n=30)、MIAE(n=32)和 NWS(n=29)。进行了人体测量评估,并采集空腹血样进行生化分析,包括血脂谱以及 PON1 和 ARE 活性。统计分析比较了各组,并评估了肥胖指标与动脉粥样硬化生物标志物之间的相关性。
与 OOS 组相比,VIBBE 组的低密度脂蛋白胆固醇(LDL-C)、甘油三酯(TG)和 TG 与高密度脂蛋白胆固醇(HDL-C)比值的对数值[log(TG/HDL-C)]显著降低(所有 P<0.05),表明血脂谱得到改善。然而,与 NWS 组相比,这些改善并不显著(P>0.05),这表明 VIBBE 可能不会提供除与正常体重状态相关的脂质谱益处之外的其他益处。与 MIAE 组相比,VIBBE 组的 PON1 和 ARE 活性显著降低(均 P<0.05),这表明 VIBBE 可能不会有效增强抗氧化防御。相关性分析显示,PON1 和 ARE 活性与肥胖指标(包括体重指数(BMI)、腰臀比(WHR)、腰高比(WHtR)、体脂百分比(BFP)、脂肪质量指数(FMI)和肥胖程度(OD))呈显著负相关(均 P<0.05)。oxLDL 与 log(TG/HDL-C)和肥胖指标呈正相关(均 P<0.05)。
高强度健身运动与静坐肥胖个体相比,可改善某些血脂参数,但不会显著增强抗氧化酶活性,也不会在正常体重静坐男性观察到的脂质谱基础上进一步改善。相反,中等强度有氧运动可显著增强 PON1 和 ARE 活性,改善血脂谱,提供更好的心血管益处。这些发现强调了将中等强度有氧运动纳入体育活动指南的重要性,通过平衡改善脂质代谢和增强抗氧化防御来优化心血管健康。
Scand J Clin Lab Invest. 2017-11-23
J Sports Med Phys Fitness. 2020-3
Physiol Res. 2007
Clin Biochem. 2007-3
Antioxidants (Basel). 2025-2-12
Biomedicines. 2023-10-26
J Clin Med. 2023-2-2
Endocrinol Metab (Seoul). 2022-2